Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

ERS Congress 2024

Keep up to date on the latest news from the annual European Respiratory Society conference.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders

Open Access 30-07-2024 | Metabolic Disease and Nutrition

Cardiometabolic effects of hypoprolactinemia

Authors: Renata S. Auriemma, Roberta Scairati, Rosa Pirchio, Guendalina Del Vecchio, Sara Di Meglio, Davide Menafra, Rosario Pivonello, Annamaria Colao

Published in: Reviews in Endocrine and Metabolic Disorders

Login to get access

Abstract

The fall of PRL levels below the lower limit of the normal range configures the condition of hypoprolactinemia. Unlike PRL excess, whose clinical features and treatments are well established, hypoprolactinemia has been only recently described as a morbid entity requiring prompt identification and proper therapeutic approach. Particularly, hypoprolactinemia has been reported to be associated with the development of metabolic syndrome and impaired cardiometabolic health, as visceral obesity, insulin-resistance, diabetes mellitus, dyslipidaemia, chronic inflammation, and sexual dysfunction have been found more prevalent in patients with hypoprolactinemia as compared to those with normoprolactinemia. This evidence has been collected mainly in patients on chronic treatment with dopamine agonists for PRL excess due to a PRL-secreting pituitary tumour, and less frequently in those receiving the atypical antipsychotic aripiprazole. Nowadays, hypoprolactinemia appears to represent a novel and unexpected risk factor for cardiovascular diseases, as is the case for hyperprolactinemia. Nevertheless, current knowledge still lacks an accurate biochemical definition of hypoprolactinemia, since no clear PRL threshold has been established to rule in the diagnosis of PRL deficiency enabling early identification of those individual subjects with increased cardiovascular risk directly ascribable to the hormonal imbalance. The current review article focuses on the effects of hypoprolactinemia on the modulation of body weight, gluco-insulinemic and lipid profile, and provides latest knowledge about potential cardiovascular outcomes of hypoprolactinemia.
Literature
1.
Hosseini K, Khalaji A, Behnoush AH, Soleimani H, Mehrban S, Amirsardari Z, Najafi K, Fathian Sabet M, Hosseini Mohammadi NS, Shojaei S, Masoudkabir F, Aghajani H, Mehrani M, Razjouyan H, Hernandez AV. The association between metabolic syndrome and major adverse cardiac and cerebrovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Sci Rep. 2024;14(1):697.PubMedPubMedCentralCrossRef
2.
Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022;13:1015520.PubMedCrossRef
3.
Macotela Y, Ruiz-Herrera X, Vázquez-Carrillo DI, Ramírez-Hernandez G, Martínez de la Escalera G, Clapp C. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne). 2022;13:1001703.PubMedCrossRef
4.
Weinhaus AJ, Stout LE, Bhagroo NV, Brelje TC, Sorenson RL. Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J Endocrinol. 2007;193(3):367–81.PubMedCrossRef
5.
Nagano M, Kelly PA. Tissue distribution and regulation of rat prolactin receptor gene expression. Quantitative analysis by polymerase chain reaction. J Biol Chem. 1994;269(18):13337–45.PubMedCrossRef
6.
Huang Y, Chang Y. Regulation of pancreatic islet beta-cell mass by growth factor and hormone signaling. Prog Mol Biol Transl Sci. 2014;121:321–49.PubMedCrossRef
7.
8.
Sorenson RL, Brelje TC, Roth C. Effects of steroid and lactogenic hormones on islets of Langerhans: a new hypothesis for the role of pregnancy steroids in the adaptation of islets to pregnancy. Endocrinology. 1993;133(5):2227–34.PubMedCrossRef
9.
Brelje TC, Scharp DW, Lacy PE, Ogren L, Talamantes F, Robertson M, Friesen HG, Sorenson RL. Effect of homologous placental lactogens, prolactins, and growth hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets: implication for placental lactogen regulation of islet function during pregnancy. Endocrinology. 1993;132(2):879–87.PubMedCrossRef
10.
Petryk A, Fleenor D, Driscoll P, Freemark M. Prolactin induction of insulin gene expression: the roles of glucose and glucose transporter-2. J Endocrinol. 2000;164(3):277–86.PubMedCrossRef
11.
Fleenor DE, Freemark M. Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5. Endocrinology. 2001;142(7):2805–10.PubMedCrossRef
12.
Møldrup A, Petersen ED, Nielsen JH. Effects of sex and pregnancy hormones on growth hormone and prolactin receptor gene expression in insulin-producing cells. Endocrinology. 1993;133(3):1165–72.PubMedCrossRef
13.
Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab. 2018;13(2):99–106.PubMedCrossRef
14.
15.
Nanbu-Wakao R, Fujitani Y, Masuho Y, Muramatu M, Wakao H. Prolactin enhances CCAAT enhancer-binding protein-beta (C/EBP beta) and peroxisome proliferator-activated receptor gamma (PPAR gamma) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells. Mol Endocrinol. 2000;14(2):307–16.PubMed
16.
Auffret J, Viengchareun S, Carré N, Denis RG, Magnan C, Marie PY, Muscat A, Fève B, Lombès M, Binart N. Beige differentiation of adipose depots in mice lacking prolactin receptor protects against high-fat-diet-induced obesity. FASEB J. 2012;26(9):3728–37.PubMedCrossRef
17.
Nilsson LA, Roepstorff C, Kiens B, Billig H, Ling C. Prolactin suppresses malonyl-CoA concentration in human adipose tissue. Horm Metab Res. 2009;41(10):747–51.PubMedCrossRef
18.
Nilsson L, Binart N, Bohlooly-Y M, Bramnert M, Egecioglu E, Kindblom J, Kelly PA, Kopchick JJ, Ormandy CJ, Ling C, Billig H. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun. 2005;331(4):1120–6.PubMedCrossRef
19.
Gualillo O, Lago F, García M, Menéndez C, Señarís R, Casanueva FF, Diéguez C. Prolactin stimulates leptin secretion by rat white adipose tissue. Endocrinology. 1999;140(11):5149–53.PubMedCrossRef
20.
Ling C, Billig H. PRL receptor-mediated effects in female mouse adipocytes: PRL induces suppressors of cytokine signaling expression and suppresses insulin-induced leptin production in adipocytes in vitro. Endocrinology. 2001;142(11):4880–90.PubMedCrossRef
21.
Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas. Front Endocrinol (Lausanne). 2019;10:327.PubMedCrossRef
22.
Landgraf R, Landraf-Leurs MM, Weissmann A, Hörl R, von Werder K, Scriba PC. Prolactin: a diabetogenic hormone. Diabetologia. 1977;13(2):99–104.PubMedCrossRef
23.
Johnston DG, Alberti KG, Nattrass M, Burrin JM, Blesa-Malpica G, Hall K, Hall R. Hyperinsulinaemia in hyperprolactinaemic women. Clin Endocrinol (Oxf). 1980;13(4):361–8.PubMedCrossRef
24.
Pelkonen R, Nikkilä EA, Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf). 1982;16(4):383–90.PubMedCrossRef
25.
Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia. 1985;28(3):138–42.PubMedCrossRef
26.
Atmaca A, Bilgici B, Ecemis GC, Tuncel OK. Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia. Endocrine. 2013;44(3):756–61.PubMedCrossRef
27.
Kok P, Roelfsema F, Frölich M, Meinders AE, Pijl H. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab. 2004;89(9):4445–9.PubMedCrossRef
28.
Berinder K, Nyström T, Höybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14(3):199–207.PubMedCrossRef
29.
Naliato EC, Violante AH, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Souza RG, Costa PL, Colao A. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf). 2007;67(6):845–52.PubMedCrossRef
30.
Naliato EC, Violante AH, Gaccione M, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Costa FS, Colao A. Body fat in men with prolactinoma. J Endocrinol Invest. 2008;31(11):985–90.PubMedCrossRef
31.
dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19(4):800–5.PubMedCrossRef
32.
Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf). 2013;79(6):845–52.PubMedCrossRef
33.
Auriemma RS, Granieri L, Galdiero M, Simeoli C, Perone Y, Vitale P, Pivonello C, Negri M, Mannarino T, Giordano C, Gasperi M, Colao A, Pivonello R. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology. 2013;98(4):299–310.PubMedCrossRef
34.
Posawetz AS, Trummer C, Pandis M, Aberer F, Pieber TR, Obermayer-Pietsch B, Pilz S, Theiler-Schwetz V. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr Disord. 2021;21(1):81.PubMedPubMedCentralCrossRef
35.
Foss MC, Paula FJ, Paccola GM, Piccinato CE. Peripheral glucose metabolism in human hyperprolactinaemia. Clin Endocrinol (Oxf). 1995;43(6):721–6.PubMedCrossRef
36.
Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest. 2003;26(4):341–6.PubMedCrossRef
37.
Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bahcec M, Tuzcu S. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary. 2009;12(4):330–4.PubMedCrossRef
38.
Erem C, Kocak M, Nuhoglu I, Yılmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf). 2010;73(4):502–7.PubMedCrossRef
39.
Auriemma RS, Galdiero M, Vitale P, Granieri L, Lo Calzo F, Salzano C, Ferreri L, Pivonello C, Cariati F, Coppola G, de Angelis C, Colao A, Pivonello R. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;101(1):66–81.PubMedCrossRef
40.
Yazici D, Sunbul M, Yasar M, Deyneli O, Yavuz D. Is there an increased cardiovascular risk in patients with prolactinoma? A challenging question J Clin Ultrasound. 2021;49(8):870–7.PubMedCrossRef
41.
Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006;64(4):366–70.PubMedCrossRef
42.
Macotela Y, Triebel J, Clapp C. Time for a New Perspective on Prolactin in Metabolism. Trends Endocrinol Metab. 2020;31(4):276–86.PubMedCrossRef
43.
Li J, Rice MS, Huang T, Hankinson SE, Clevenger CV, Hu FB, Tworoger SS. Circulating prolactin concentrations and risk of type 2 diabetes in US women. Diabetologia. 2018;61(12):2549–60.PubMedPubMedCentralCrossRef
44.
Wang T, Xu Y, Xu M, Ning G, Lu J, Dai M, Xu B, Sun J, Sun W, Lai S, Bi Y, Wang W. Circulating Prolactin and Risk of Type 2 Diabetes: A Prospective Study. Am J Epidemiol. 2016;184(4):295–301.PubMedCrossRef
45.
Wang T, Lu J, Xu Y, Li M, Sun J, Zhang J, Xu B, Xu M, Chen Y, Bi Y, Wang W, Ning G. Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care. 2013;36(7):1974–80.PubMedPubMedCentralCrossRef
46.
Glintborg D, Altinok M, Mumm H, Buch K, Ravn P, Andersen M. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. Hum Reprod. 2014;29(8):1773–9.PubMedCrossRef
47.
Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, Boddi V, Bandini E, Balercia G, Forti G, Maggi M. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med. 2009;6(5):1457–66.PubMedCrossRef
48.
Zhang P, Ge Z, Wang H, Feng W, Sun X, Chu X, Jiang C, Wang Y, Zhu D, Bi Y. Prolactin improves hepatic steatosis via CD36 pathway. J Hepatol. 2018;68(6):1247–55.PubMedCrossRef
49.
Ruiz-Herrera X, de Los Ríos EA, Díaz JM, Lerma-Alvarado RM, Martínez de la Escalera L, López-Barrera F, Lemini M, Arnold E, Martínez de la Escalera G, Clapp C, Macotela Y. Prolactin Promotes Adipose Tissue Fitness and Insulin Sensitivity in Obese Males. Endocrinology. 2017;158(1):56–68.PubMed
50.
Hawkins TA, Gala RR, Dunbar JC. Prolactin modulates the incidence of diabetes in male and female NOD mice. Autoimmunity. 1994;18(3):155–62.PubMedCrossRef
51.
de Moura EG, Bonomo IT, Nogueira-Neto JF, de Oliveira E, Trevenzoli IH, Reis AM, Passos MC, Lisboa PC. Maternal prolactin inhibition during lactation programs for metabolic syndrome in adult progeny. J Physiol. 2009;587(Pt 20):4919–29.PubMedPubMedCentralCrossRef
52.
Bonomo IT, Lisboa PC, Pereira AR, Passos MC, de Moura EG. Prolactin inhibition in dams during lactation programs for overweight and leptin resistance in adult offspring. J Endocrinol. 2007;192(2):339–44.PubMedCrossRef
53.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–30.PubMedPubMedCentralCrossRef
54.
Prencipe N, Marinelli L, Varaldo E, Cuboni D, Berton AM, Bioletto F, Bona C, Gasco V, Grottoli S. Isolated anterior pituitary dysfunction in adulthood. Front Endocrinol (Lausanne). 2023;14:1100007.PubMedCrossRef
55.
Kauppila A, Chatelain P, Kirkinen P, Kivinen S, Ruokonen A. Isolated prolactin deficiency in a woman with puerperal alactogenesis. J Clin Endocrinol Metab. 1987;64(2):309–12.PubMedCrossRef
56.
57.
Zargar AH, Masoodi SR, Laway BA, Shah NA, Salahudin M. Familial puerperal alactogenesis: possibility of a genetically transmitted isolated prolactin deficiency. Br J Obstet Gynaecol. 1997;104(5):629–31.PubMedCrossRef
58.
Douchi T, Nakae M, Yamamoto S, Iwamoto I, Oki T, Nagata Y. A woman with isolated prolactin deficiency. Acta Obstet Gynecol Scand. 2001;80(4):368–70.PubMed
59.
Iwama S, Welt CK, Romero CJ, Radovick S, Caturegli P. Isolated prolactin deficiency associated with serum autoantibodies against prolactin-secreting cells. J Clin Endocrinol Metab. 2013;98(10):3920–5.PubMedPubMedCentralCrossRef
60.
Callejas L, Berens P, Nader S. Breastfeeding failure secondary to idiopathic isolated prolactin deficiency: report of two cases. Breastfeed Med. 2015;10(3):183.PubMedCrossRef
61.
Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722–40.PubMedCrossRef
62.
Krøigaard SM, Clemmensen L, Tarp S, Pagsberg AK. A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents. J Child Adolesc Psychopharmacol. 2022;32(7):374–89.PubMedCrossRef
63.
Vranic M, Ahmed F, Hetty S, Sarsenbayeva A, Ferreira V, Fanni G, Valverde ÁM, Eriksson JW, Pereira MJ. Effects of the second-generation antipsychotic drugs aripiprazole and olanzapine on human adipocyte differentiation. Mol Cell Endocrinol. 2023;561: 111828.PubMedCrossRef
64.
Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349(21):2023–33.PubMedCrossRef
65.
Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf). 2007;67(3):426–33.PubMedCrossRef
66.
Mukherjee A, Ryder WD, Jöstel A, Shalet SM. Prolactin deficiency is independently associated with reduced insulin-like growth factor I status in severely growth hormone-deficient adults. J Clin Endocrinol Metab. 2006;91(7):2520–5.PubMedCrossRef
67.
Maseroli E, Corona G, Rastrelli G, Lotti F, Cipriani S, Forti G, Mannucci E, Maggi M. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med. 2015;12(4):956–65.PubMedCrossRef
68.
Sogawa R, Shimomura Y, Minami C, Maruo J, Kunitake Y, Mizoguchi Y, Kawashima T, Monji A, Hara H. Aripiprazole-Associated Hypoprolactinemia in the Clinical Setting. J Clin Psychopharmacol. 2016;36(4):385–7.PubMedCrossRef
69.
Ponce AJ, Galván-Salas T, Lerma-Alvarado RM, Ruiz-Herrera X, Hernández-Cortés T, Valencia-Jiménez R, Cárdenas-Rodríguez LE, Martínez de la Escalera G, Clapp C, Macotela Y. Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans. Endocrine. 2020;67(2):331–43.PubMedCrossRef
70.
Krysiak R, Kowalcze K, Okopień B. Sexual function and depressive symptoms in young women with hypoprolactinaemia. Clin Endocrinol (Oxf). 2020;93(4):482–8.PubMedCrossRef
71.
Tasaki M, Yasui-Furukori N, Yokoyama S, Shinozaki M, Sugawara N, Shimoda K. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacol Rep. 2021;41(3):379–84.PubMedPubMedCentralCrossRef
72.
73.
Krysiak R, Kowalcze K, Okopień B. Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study. Cardiology. 2022;147(5–6):497–506.PubMedCrossRef
74.
75.
Maseroli E, Verde N, Cipriani S, Rastrelli G, Alfaroli C, Ravelli SA, Costeniero D, Scairati R, Minnetti M, Petraglia F, Auriemma RS, Nappi RE, Maggi M, Vignozzi L. Low prolactin level identifies hypoactive sexual desire disorder women with a reduced inhibition profile. J Endocrinol Invest. 2023;46(12):2481–92.PubMedPubMedCentralCrossRef
76.
Corona G, Rastrelli G, Boddi V, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Int J Androl. 2011;34(3):217–24.PubMedCrossRef
77.
Colao A, Di Somma C, Savanelli MC, De Leo M, Lombardi G. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res. 2006;16 Suppl A:S41-8.PubMedCrossRef
78.
Nielsen EH, Lindholm J, Laurberg P. Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf). 2007;67(5):693–7.PubMedCrossRef
79.
Dilixiati D, Cao R, Mao Y, Li Y, Dilimulati D, Azhati B, Rexiati M. Association between cardiovascular disease and risk of female sexual dysfunction: A systematic review and meta-analysis. Eur J Prev Cardiol. 2024;31(7):782–800.PubMedCrossRef
80.
Raheem OA, Su JJ, Wilson JR, Hsieh TC. The association of erectile dysfunction and cardiovascular disease: A systematic critical review. Am J Mens Health. 2017;11(3):552–63.PubMedCrossRef
81.
Zhao B, Hong Z, Wei Y, Yu D, Xu J, Zhang W. Erectile dysfunction predicts cardiovascular events as an independent risk factor: A systematic review and meta-analysis. J Sex Med. 2019;16(7):1005–17.PubMedCrossRef
Metadata
Title
Cardiometabolic effects of hypoprolactinemia
Authors
Renata S. Auriemma
Roberta Scairati
Rosa Pirchio
Guendalina Del Vecchio
Sara Di Meglio
Davide Menafra
Rosario Pivonello
Annamaria Colao
Publication date
30-07-2024

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits